IDEAYA BIOSCIENCES ANNOUNCES IDE892, A POTENTIAL BEST-IN-CLASS MTA-COOPERATIVE PRMT5 INHIBITOR, INITIATES PART 2 MONOTHERAPY EXPANSION IN THE PHASE 1/2 STUDY IN MTAP-DELETED PANCREATIC AND LUNG CANCERS

Reuters · 2d ago

Please log in to view news